This website uses cookies to enhance the user experience.
BEVITAL AS

BEVITAL AS985 694 931

Research
Limited company
Minde allé 35 5068 BERGEN, Norge

BEVITAL AS

Targeted metabolomics services - BEVITAL AS
High-precision targeted metabolomics by authentic isotope-labelled standards. Olink PEA panels for high-quality proteomics. Customized scientific support.

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

Chairman of the board
Years since formation
21 years
since May 21, 2003
Type
Limited company
VAT registered
Yes
Number of employees
12

Ownership

Number of shares and share classes
100
1 share class
Total number of shareholders
1
company
Belongs to group of

Financials

Total operating income 2023
12,262,372
NOK
Annual total result 2023
-2,418,309
NOK
Total equity 2023
-1,535,508
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Chairman-
Deputy Chair-
Board Member-
Board Member-
Alternate Member-
Alternate Member-
Board Member-

Others

NameRoleShares
S
SIGMA REVISJON AS
Auditor-
E
ECIT SERVICES AS
Accountant-
Last update: Sep 13, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
Ordinary shares
100
100 %
Last update: May 24, 2024

Group structure

Financials

in NOK

Summary

Year202320222021
Total operating income
12,262,372
10,554,125
7,329,256
Annual Total Result
-2,418,309
-2,397,059
-6,822,517
Total assets
7,945,641
7,356,605
5,627,068
Total liabilities
9,481,149
6,473,804
53,305,456
Total equity
-1,535,508
882,801
-47,678,388

P&L

Year202320222021
Total operating income
12,262,372
10,554,125
7,329,256
Total operating costs
14,795,295
12,713,786
13,429,627
Operating result
-2,532,923
-2,159,661
-6,100,371
Financial income/costs
114,613
-237,398
-722,147
Profit before tax
-2,418,309
-2,397,059
-6,822,517
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
-2,418,309
-2,397,059
-6,822,517

Balance overview

Year202320222021
Total fixed assets
2,465,988
1,431,888
1,670,811
Total current assets
5,479,652
5,924,718
3,956,258
Total assets
7,945,641
7,356,605
5,627,068
Short term debt
7,146,369
5,214,267
4,428,837
Long term debt
2,334,779
1,259,538
48,876,620
Total liabilities
9,481,149
6,473,804
53,305,456
Contributed capital
1,000,000
1,000,000
500,000
Retained earnings
-2,535,508
-117,199
-48,178,388
Total equity
-1,535,508
882,801
-47,678,388
Total equity and liabilities
7,945,641
7,356,605
5,627,068

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology